Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
Takeda Delivers Double-Digit Profit Growth as Entyvio Nets 200-Plus Billion Yen
Takeda Pharmaceutical notched up double-digit profit growth in the year ended in March on group revenues of 1.77 trillion yen, which rose 2.2% over the previous year as bullish Entyvio (vedolizumab) sales more than offset a decline stemming from the…
To read the full story
Related Article
- Takeda Sees 18.5% Sales Rise after Shire Buy, but Braces for Losses in FY2019
May 15, 2019
- Takeda Sees Flat Sales as Brisk US Revenue Offset by Off-Patent Divestiture
November 1, 2018
- Velcade Sales Would Slide 50%, but Weber Stresses Takeda’s Strong Momentum
May 15, 2018
- Takeda Logs 3.6% Sales Rise, Double-Digit Profit Jump on Entyvio, Takecab
November 2, 2017
- Takeda’s Japan Ethical Sales Sag 6.8% on LLP Transfer, but Underlining Revenue Grows
May 11, 2017
BUSINESS
- Kaken’s Head Lice Lotion Hits PIII Goal, Filing Eyed in 1st Half of FY2026
December 9, 2025
- LinqMed Builds Radiopharma Plant in Rare Manufacturing Bet for Biotech Startup
December 9, 2025
- Kazuo Nakamura, Founder of Japan’s First CRO, Dies at 78
December 9, 2025
- Erbitux-Braftovi Combo Now Available for Frontline BRAF-Mutant Colorectal Cancer in Japan
December 9, 2025
- Limited Sites, Bed Capacity Seen as Key Hurdles to Radioligand Therapy Uptake: Urologist
December 8, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…